Payment overview · 2025
General Payments
$1,122.26
26 reported records · 11 companies
Healthcare provider profile · identity verified
Yogesh Kumar Trehan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRENTWOOD, CA · NPI 1255372769
Verified facts
What the public records show
CMS Open Payments records show Yogesh Kumar Trehan, M.D. received $1,122.26 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $544.90 | 48.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.56 | 15.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.25 | 12.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.16 | 7.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.24 | 3.8% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.51 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.80 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.07 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.01 | 1.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $18.51 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.25 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.26 | 25 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $450.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $509.75 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $149.48 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.48 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 924 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 641 | 165 |
| Losartan Potassium | Losartan Potassium | 394 | 112 |
| Lisinopril | Lisinopril | 368 | 107 |
| Metformin Hcl | Metformin Hcl | 363 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 90 |
| Simvastatin | Simvastatin | 297 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 70 |
| Sertraline Hcl | Sertraline Hcl | 223 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 220 | 39 |
| Furosemide | Furosemide | 210 | 69 |
| Gabapentin | Gabapentin | 205 | 64 |
| Omeprazole | Omeprazole | 201 | 56 |
| Eliquis | Apixaban | 188 | 35 |
| Allopurinol | Allopurinol | 179 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 50 |
| Trazodone Hcl | Trazodone Hcl | 164 | 41 |
| Alprazolam | Alprazolam | 161 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 73 |
| Atenolol | Atenolol | 152 | 46 |
| Donepezil Hcl | Donepezil Hcl | 149 | 34 |
| Lorazepam | Lorazepam | 126 | 29 |
| Azithromycin | Azithromycin | 124 | 90 |
| Ezetimibe | Ezetimibe | 120 | 35 |
| Carvedilol | Carvedilol | 118 | 36 |
| Famotidine | Famotidine | 111 | 24 |
| Valsartan | Valsartan | 111 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 37 |
| Montelukast Sodium | Montelukast Sodium | 104 | 28 |
| Ozempic | Semaglutide | 101 | 21 |
| Metformin Hcl Er | Metformin Hcl | 99 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 22 |
| Potassium Chloride | Potassium Chloride | 78 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 61 |
| Celecoxib | Celecoxib | 76 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 24 |
| Irbesartan | Irbesartan | 74 | 23 |
| Benazepril Hcl | Benazepril Hcl | 65 | 18 |
| Finasteride | Finasteride | 65 | 18 |
| Prednisone | Prednisone | 62 | 40 |
| Jardiance | Empagliflozin | 61 | 15 |
| Xarelto | Rivaroxaban | 61 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 20 |
| Memantine Hcl | Memantine Hcl | 59 | 13 |
| Glimepiride | Glimepiride | 58 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 11 |
| Bupropion Xl | Bupropion Hcl | 57 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 26 |
| Cephalexin | Cephalexin | 56 | 39 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 28 |
| Ibuprofen | Ibuprofen | 52 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 11 |
| Tramadol Hcl | Tramadol Hcl | 50 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 28 |
| Fenofibrate | Fenofibrate | 49 | 11 |
| Glipizide | Glipizide | 49 | 11 |
| Promethazine Hcl | Promethazine Hcl | 49 | 19 |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Lovastatin | Lovastatin | 45 | 14 |
| Farxiga | Dapagliflozin Propanediol | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 13 |
| Azelastine Hcl | Azelastine Hcl | 40 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Buspirone Hcl | Buspirone Hcl | 36 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 18 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 12 |
| Temazepam | Temazepam | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 12 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 22 | 21 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 13 |
| Valacyclovir | Valacyclovir Hcl | 21 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,122.26 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OFEV, Ozempic, QULIPTA, SPINRAZA, UBRELVY, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error